Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In vitro fertilization devices

This article was originally published in The Gray Sheet

Executive Summary

Makers of IVF devices already in commercial distribution will be allowed to continue marketing the products provided that they have submitted a 510(k) for each device marketed in the U.S. within 60 days, FDA says in a letter posted on its website Feb. 19. Additionally, makers of the devices, which were reclassified into either Class II or Class I in October ("The Gray Sheet" Sept. 14, 1998, p. 16), must register their products and list their establishments with the agency. Adherence to the quality system regulation and "other pertinent FDA regulations," such as medical device reporting, labeling and corrections and removals, also is required. Firms in compliance with the stipulations and the reclassification document may continue marketing their devices until FDA determines that the products are substantially equivalent. Devices found not substantially equivalent will require a premarket application approval to be approved before marketing may resume, the agency says

You may also be interested in...

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts